Omeros stock slips 1.47 percent after Cantor upgrade

Published on 09/24/2026 at 11:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Omeros stock followed second-quarter revenue of USD 28.53 million on September 23, 2026. Adjusted EPS reached USD 0.02 against a USD 0.27 loss consensus.

OMER, US6821431029, Illustration mit AI erstellt.

Omeros Corporation (ISIN US6821431029) stood at USD 20.74 on Nasdaq on September 23, 2026, down 1.47 percent from the previous close. The move followed a sharp analyst upgrade on September 22, when Cantor Fitzgerald raised Omeros from Neutral to Overweight and set a USD 22.00 price target, according to Investing.com.

Q2 figures reset expectations

Omeros reported USD 28.53 million in revenue for the second quarter ended June 30, 2026, compared with a USD 12.69 million consensus estimate. The same quarter produced adjusted EPS of USD 0.02, while the consensus estimate called for a loss of USD 0.27, according to MarketBeat.

The numbers give the Yartemlea launch a measurable commercial dimension. Revenue exceeded the consensus estimate by USD 15.84 million, while adjusted EPS moved USD 0.29 above the expected loss. That combination explains why the analyst reaction centered on future sales potential rather than only on quarterly profitability.

Yartemlea drives the upgrade

Cantor Fitzgerald reinstated its USD 22.00 target after reviewing the early performance of Yartemlea, Omeros's therapy for transplant-associated thrombotic microangiopathy. The rating change and target were reported on September 22, 2026, by TradingView.

The target sits USD 1.26 above the September 23 price, a 6.1 percent difference. That gap is smaller than the distance between the current quote and the 52-week high, which leaves the market weighing immediate execution against the valuation already embedded in the stock.

Stock remains near yearly high

Omeros stock was 2.4 percent below its 52-week high of USD 21.24 on September 23, 2026. The 52-week range extended down to USD 4.06, showing how far the current quote has moved within the past year.

The company had a market capitalization of USD 1,501,064,863 on September 23, 2026. For investors, the central calculation is now whether quarterly revenue of USD 28.53 million can develop into a durable commercial base for Yartemlea.